A groundbreaking AI-powered risk prediction tool, P-CARDIAC, is set to revolutionize CVD prevention and management in the Chinese population, led by Professor Celine Chui Sze-ling at The University of Hong Kong. The HEARTWISE study will evaluate P-CARDIAC's effectiveness in secondary care, focusing on personalized risk assessment, risk thresholds, and pharmacist-led services. The study aims to reduce CVD burden in Hong Kong and beyond, with potential global impact.